Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease

Sebastiaan Ten Bokkel Huinink; Vince Biemans; Marjolijn Duijvestein; Marieke Pierik; Frank Hoentjen; Rachel L West; Christien J van der Woude; Annemarie C de Vries

doi:10.1097/MEG.0000000000002256

Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease

Sebastiaan Ten Bokkel Huinink, Vince Biemans, Marjolijn Duijvestein, Marieke Pierik, Frank Hoentjen, Rachel L West, Christien J van der Woude, Annemarie C de Vries^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	e783-e788
Number of pages	6
Journal	European Journal of Gastroenterology & Hepatology
Volume	33
Issue number	1S Suppl 1
DOIs	https://doi.org/10.1097/MEG.0000000000002256
Publication status	Published - 1 Dec 2021

Keywords

Crohn's disease
treatment failure
Ustekinumab
MAINTENANCE THERAPY
MODERATE

Access to Document

10.1097/MEG.0000000000002256

Cite this

Ten Bokkel Huinink, S., Biemans, V., Duijvestein, M., Pierik, M., Hoentjen, F., West, R. L., van der Woude, C. J., & de Vries, A. C. (2021). Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease. European Journal of Gastroenterology & Hepatology, 33(1S Suppl 1), e783-e788. https://doi.org/10.1097/MEG.0000000000002256

Ten Bokkel Huinink, Sebastiaan ; Biemans, Vince ; Duijvestein, Marjolijn ; Pierik, Marieke ; Hoentjen, Frank ; West, Rachel L ; van der Woude, Christien J ; de Vries, Annemarie C. / Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease. In: European Journal of Gastroenterology & Hepatology. 2021 ; Vol. 33, No. 1S Suppl 1. pp. e783-e788.

@article{d3e79855be374333a8eddc8010e922fa,

title = "Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease",

keywords = "Crohn's disease, treatment failure, Ustekinumab, MAINTENANCE THERAPY, MODERATE",

author = "{Ten Bokkel Huinink}, Sebastiaan and Vince Biemans and Marjolijn Duijvestein and Marieke Pierik and Frank Hoentjen and West, {Rachel L} and {van der Woude}, {Christien J} and {de Vries}, {Annemarie C}",

year = "2021",

month = dec,

day = "1",

doi = "10.1097/MEG.0000000000002256",

language = "English",

volume = "33",

pages = "e783--e788",

journal = "European Journal of Gastroenterology & Hepatology",

issn = "0954-691X",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "1S Suppl 1",

}

Ten Bokkel Huinink, S, Biemans, V, Duijvestein, M, Pierik, M, Hoentjen, F, West, RL, van der Woude, CJ & de Vries, AC 2021, 'Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease', European Journal of Gastroenterology & Hepatology, vol. 33, no. 1S Suppl 1, pp. e783-e788. https://doi.org/10.1097/MEG.0000000000002256

Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease. / Ten Bokkel Huinink, Sebastiaan; Biemans, Vince; Duijvestein, Marjolijn; Pierik, Marieke; Hoentjen, Frank; West, Rachel L; van der Woude, Christien J; de Vries, Annemarie C.

In: European Journal of Gastroenterology & Hepatology, Vol. 33, No. 1S Suppl 1, 01.12.2021, p. e783-e788.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease

AU - Ten Bokkel Huinink, Sebastiaan

AU - Biemans, Vince

AU - Duijvestein, Marjolijn

AU - Pierik, Marieke

AU - Hoentjen, Frank

AU - West, Rachel L

AU - van der Woude, Christien J

AU - de Vries, Annemarie C

PY - 2021/12/1

Y1 - 2021/12/1

KW - Crohn's disease

KW - treatment failure

KW - Ustekinumab

KW - MAINTENANCE THERAPY

KW - MODERATE

U2 - 10.1097/MEG.0000000000002256

DO - 10.1097/MEG.0000000000002256

M3 - Article

C2 - 34334713

VL - 33

SP - e783-e788

JO - European Journal of Gastroenterology & Hepatology

JF - European Journal of Gastroenterology & Hepatology

SN - 0954-691X

IS - 1S Suppl 1

ER -